China, U.S. Drug Pact Addresses U.S. Security Issues (China)
This article was originally published in PharmAsia News
Executive SummaryU.S. concerns about the safety of drugs imported from China have as much to do with U.S. national security issues as with the safety of the medicines themselves. As an example, China and India are the only sources of key ingredients for two antibiotics considered the only ones suited to treat anthrax if an attack on the U.S. leaves the country short of supplies. The main component of anti-anthrax treatments, doxycycline, is made only in China. But drug-oversight scandals in China, which led to the execution of an official of the State FDA that oversees a $65 billion pharmaceutical industry, are seen as potential problems for the United States. (Click here for more ) "China's Monopoly On Pharmaceuticals Raises U.S., Europe Security Concerns" Taiwan News (12/10/07)
You may also be interested in...
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.
As part of its response to the coronavirus outbreak, Medicines for Europe has set out a series of policy recommendations that it says could help to mitigate the risks of COVID-19.
The coronavirus COVID-19 outbreak poses a “limited immediate risk” to European production and supplies of off-patent drugs, according to industry association Medicines for Europe. However, if the situation continues for an extended period an “important impact” cannot be ruled out.